SCHEMBL15933252

SCHEMBL15933252

CC(=O)c1cnn(-c2cc(Cl)ccc2O)c1C

nearest known ligand 0.58

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPK1 P28482 2/20 0.58
RAB9A P51151 5/20 0.42
NPC1 O15118 3/20 0.42
SMN1; SMN2 Q16637 3/20 0.42
MAPT P10636 2/20 0.42
HPGD P15428 2/20 0.42
KDM4E B2RXH2 2/20 0.42
KMT2A Q03164 2/20 0.41
MEN1 O00255 1/20 0.41
L3MBTL1 Q9Y468 1/20 0.41
P2RY12 Q9H244 1/20 0.39
P2RX1 P51575 1/20 0.39
TMPRSS4 Q9NRS4 1/20 0.39
MYC P01106 1/20 0.38
IDO1 P14902 1/20 0.38
CA1 P00915 1/20 0.38
CA2 P00918 1/20 0.38
NOTUM Q6P988 1/20 0.38
ALDH1A1 P00352 1/20 0.38
TDP1 Q9NUW8 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL14692560 0.89 CA1 (0.49) MAPK1RAB9ANPC1SMN1; SMN2HPGD
SCHEMBL15930149 0.85 MAPK1 (0.42) MAPK1RAB9ANPC1KDM4EKMT2A
SCHEMBL15933284 0.83 MAPK1 (0.54) MAPK1RAB9ANPC1SMN1; SMN2MAPT
SCHEMBL13832785 0.78 MAPK1 (0.71) MAPK1RAB9ANPC1SMN1; SMN2MAPT
SCHEMBL6345488 0.77 MAPK1 (0.70) MAPK1RAB9ANPC1SMN1; SMN2MAPT
SCHEMBL7747571 0.77 CLK1 (0.53) MAPK1SMN1; SMN2MAPTKMT2AMEN1
SCHEMBL15933288 0.75 MAPK1 (0.58) MAPK1RAB9ANPC1SMN1; SMN2MAPT
SCHEMBL7239927 0.74 MAPK1 (0.57) MAPK1RAB9ANPC1SMN1; SMN2MAPT
SCHEMBL7229595 0.74 MAPK1 (1.00) MAPK1RAB9ANPC1SMN1; SMN2MAPT
SCHEMBL13576996 0.73 MAPK1 (0.52) MAPK1RAB9ANPC1SMN1; SMN2MAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9902742-B2 Macrocycles as factor XIa inhibitors BRISTOL-MYERS SQUIBB COMPANY (US) 2018-02-27 US disclosed
US-20170158712-A1 NOVEL MACROCYCLES AS FACTOR XIA INHIBITORS BRISTOL MYERS SQUIBB CO (US) 2017-06-08 US disclosed
EP-2739628-B1 NOVEL MACROCYCLES AS FACTOR XIA INHIBITORS BRISTOL MYERS SQUIBB CO (US) 2017-06-07 EP disclosed
US-9611274-B2 Macrocycles as factor XIa inhibitors BRISTOL-MYERS SQUIBB COMPANY (US) 2017-04-04 US disclosed
US-20160068544-A1 NOVEL MACROCYCLES AS FACTOR XIA INHIBITORS BRISTOL MYERS SQUIBB CO (US) 2016-03-10 US disclosed
US-9221818-B2 Macrocycles as factor XIa inhibitors BRISTOL-MYERS SQUIBB COMPANY (US) 2015-12-29 US disclosed
US-20140221338-A1 NOVEL MACROCYCLES AS FACTOR XIA INHIBITORS BRISTOL-MYERS SQUIBB COMPANY (US) 2014-08-07 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20160068544-A1 NOVEL MACROCYCLES AS FACTOR XIA INHIBITORS TFPI, TFPI2, F12 MAPK1 540/4885RAB9A 2781/4885NPC1 2191/4885
US-20140221338-A1 NOVEL MACROCYCLES AS FACTOR XIA INHIBITORS TFPI, TFPI2, F12 MAPK1 540/4885RAB9A 2781/4885NPC1 2191/4885
US-20170158712-A1 NOVEL MACROCYCLES AS FACTOR XIA INHIBITORS TFPI, TFPI2, F12 MAPK1 540/4885RAB9A 2781/4885NPC1 2191/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.